Glycinebetaine

SCHEMBL8747327

CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.CNCC(=O)O.C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-].C[N+](C)(C)CC(=O)[O-]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

BHMT BHMT2

The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	TSHR	P16473	1/20	0.46

▸	APEX1	P27695	2/20	0.44

▸	ALDH1A1	P00352	1/20	0.44

▸	LMNA	P02545	1/20	0.44

▸	CTH	P32929	1/20	0.34

▸	BBOX1	O75936	1/20	0.33

▸	SLC22A16	Q86VW1	1/20	0.33

▸	CRAT	P43155	1/20	0.32

▸	CPT2	P23786	1/20	0.31

▸	CPT1A	P50416	1/20	0.31

▸	CA4	P22748	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Glycinebetaine SCHEMBL8858999	1.00	TSHR (0.46)	TSHRAPEX1ALDH1A1LMNACTH
Glycinebetaine SCHEMBL4541516	0.93	TSHR (0.40)	TSHRAPEX1ALDH1A1LMNACTH
Glycinebetaine SCHEMBL156936	0.82	TSHR (0.46)	TSHRAPEX1ALDH1A1LMNABBOX1
Glycinebetaine SCHEMBL9281697	0.79	TSHR (0.55)	TSHRAPEX1ALDH1A1LMNABBOX1
Glycinebetaine SCHEMBL8678519	0.79	TSHR (0.53)	TSHRAPEX1ALDH1A1LMNABBOX1
Glycinebetaine SCHEMBL2803780	0.79	TSHR (0.53)	TSHRAPEX1ALDH1A1LMNABBOX1
Betaine SCHEMBL31467313	0.79	—	—
Glycinebetaine SCHEMBL4900209	0.79	—	—
Glycinebetaine SCHEMBL7739	0.79	—	—
Sarcosine SCHEMBL31612550	0.79	—	—

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-0760402-A1	Carbon dioxide steel corrosion inhibition with synergetic, environmental friendly composition of N-acyl sarcosines and N-alkyl-amidopropylbetaines	CECA S.A. (FR)	1997-03-05	—	—	EP	disclosed